Teva faces backlash over acquisitions


Consumer advocates concerned about the impact of consolidation in the generic drug industry on prices and supply have not been mollified by pharmaceutical giant Teva’s sudden decision to drop its bid for Mylan and, instead, to buy Allergan’s generic drug business. After having joined a group of critics that had